Patents by Inventor Liya SHEN

Liya SHEN has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Method of inhibiting the proliferation of T and/or B lymphocytes via dimethylarginine derivatives and lymphocytes proliferation inhibitor
    Patent number: 11654126
    Abstract: The present invention belongs to the technical field of immunotherapy. A method of using dimethylarginine derivatives to inhibit the proliferation of lymphocyte. ADMA, SDMA, and their derivative DMGV can inhibit T cells and/or B cells proliferation in vitro by inducing mitochondrial ROS. ADMA and SDMA can induce mitochondrial ROS generation by the action of alanine-glyoxylate aminotransferase 2 (AGXT2), which converts both ADMA and SDMA into dimethylguanidino valeric acid (DMGV) in the mitochondria. The dimethylarginine dimethylamino hydrolase (DDAH) inhibitor PD404182 also inhibits T cell proliferation by allowing more ADMA and SDMA to be converted to DMGV. As a clinical relevance, DMGV effectively treated arthritis in mice which was caused by activated T cells.
    Type: Grant
    Filed: August 13, 2020
    Date of Patent: May 23, 2023
    Assignee: GUANGZHOU MEDICAL UNIVERSITY
    Inventors: Jongdae Lee, Fengyuan Yang, Liya Shen
  • Method of using PRD, PRD-S TAD, ZF7 peptide or mixture thereof to inhibit cellular response to inflammatory stimuli or treat cytokine-storm-mediated diseases
    Patent number: 11648291
    Abstract: The disclosure discloses a method of using PRD, PRD-S, TAD, ZF7 peptide or a mixture thereof to inhibit a cellular response to inflammatory stimuli or treat cytokine-storm-mediated diseases. An amino acid sequence of the PRD peptide is SEQ ID NO: 1, an amino acid sequence of the PRD-S peptide is SEQ ID NO: 2, an amino acid sequence of the TAD peptide is SEQ ID NO: 3, and an amino acid sequence of the ZF7 peptide is SEQ ID NO: 4.
    Type: Grant
    Filed: August 2, 2021
    Date of Patent: May 16, 2023
    Assignee: GUANGZHOU MEDICAL UNIVERSITY
    Inventors: Jongdae Lee, Fengyuan Yang, Liya Shen, Dengxia Fan
  • METHOD OF USING PRD, PRD-S, TAD, ZF7 PEPTIDE OR MIXTURE THEREOF TO INHIBIT CELLULAR RESPONSE TO INFLAMMATORY STIMULI OR TREAT CYTOKINE-STORM-MEDIATED DISEASES
    Publication number: 20220160826
    Abstract: The disclosure discloses a method of using PRD, PRD-S, TAD, ZF7 peptide or a mixture thereof to inhibit a cellular response to inflammatory stimuli or treat cytokine-storm-mediated diseases.
    Type: Application
    Filed: August 2, 2021
    Publication date: May 26, 2022
    Applicant: GUANGZHOU MEDICAL UNIVERSITY
    Inventors: Jongdae LEE, Fengyuan YANG, Liya SHEN, Dengxia FAN
  • METHOD OF INHIBITING THE PROLIFERATION OF T AND/OR B LYMPHOCYTES VIA DIMETHYLARGININE DERIVATIVES AND LYMPHOCYTES PROLIFERATION INHIBITOR
    Publication number: 20210196660
    Abstract: The present invention belongs to the technical field of immunotherapy. A method of using dimethylarginine derivatives to inhibit the proliferation of lymphocyte. ADMA, SDMA, and their derivative DMGV can inhibit T cells and/or B cells proliferation in vitro by inducing mitochondrial ROS. ADMA and SDMA can induce mitochondrial ROS generation by the action of alanine-glyoxylate aminotransferase 2 (AGXT2), which converts both ADMA and SDMA into dimethylguanidino valeric acid (DMGV) in the mitochondria. The dimethylarginine dimethylamino hydrolase (DDAH) inhibitor PD404182 also inhibits T cell proliferation by allowing more ADMA and SDMA to be converted to DMGV. As a clinical relevance, DMGV effectively treated arthritis in mice which was caused by activated T cells.
    Type: Application
    Filed: August 13, 2020
    Publication date: July 1, 2021
    Applicant: GUANGZHOU MEDICAL UNIVERSITY
    Inventors: Jongdae LEE, Fengyuan YANG, Liya SHEN